25I-NBOMe vs LSD
A side-by-side research comparison of 25I-NBOMe and LSD across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 25I-NBOMe | LSD |
|---|---|---|
| Full name | 2C-I-NBOMe (N-bomb) | Lysergic acid diethylamide |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (high-risk research compound) | Schedule I (research compound) |
| Mechanism | A very strong serotonin 5-HT2A receptor agonist active at sub-milligram doses. | Activates serotonin 5-HT2A receptors (and others), changing perception, mood and the way brain networks communicate. Effects last much longer than most psychedelics. |
| Molecular weight | 427.33 g/mol | 323.43 g/mol |
| Half-life | Short-moderate | ~3-5 hours |
| Bioavailability | Oral | Oral |
| Typical dose | Varies by individual and setting | 100-200 mcg in clinical trials |
| Frequency | Occasional | One to a few supervised sessions |
| Route | Sublingual (must not be swallowed) | Oral, in a supervised therapeutic setting |
25I-NBOMe reported benefits
- Listed for awareness and harm reduction
- Often mis-sold as LSD (know the difference)
- NBOMe research compound
LSD reported benefits
- Studied for anxiety in serious illness
- Explored for depression and addiction
- Long duration allows deep therapeutic work
- Renewed clinical research interest
Related comparisons
Research and educational reference only. Not medical advice.